Johnson & Johnson (JNJ) Stock Analysis
Is JNJ a good investment?
Johnson & Johnson (JNJ) has a Plutrex AI rating of 72.5/100 as of May 26, 2026, indicating a Buy consensus. The stock is halal-compliant per AAOIFI standards. Key strength: Exceptional profitability with ROE 26.4% and net margin 21.8% leading peers. Main concern: PEG ratio 1.93 indicates significant overvaluation relative to 9.8% growth expectations.
Investment Summary
JNJ presents a quality dividend aristocrat with exceptional profitability (ROE 26.4% vs industry ~15%, net margin 21.8% vs peers 19.3%) but faces valuation headwinds with PEG ratio of 1.93 indicating overvaluation. Forward EPS growth of 9.8% trails industry average of 15.2% by 36%, creating a growth-value mismatch. Strong balance sheet (D/E 0.46 vs industry 1.27) and $22B cash provide stability. Positive news flow around TrumpRx platform launch and AI drug development acceleration supports near-term sentiment, but doesn't address core valuation concerns.
Key Strengths
- Exceptional profitability with ROE 26.4% and net margin 21.8% leading peers
- Superior financial health with D/E ratio 63% below industry average
- Strong cash generation with $12.5B free cash flow supporting dividend growth
Key Concerns
- PEG ratio 1.93 indicates significant overvaluation relative to 9.8% growth expectations
- Forward EPS growth 36% below industry average creates competitive disadvantage
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
Exceptional profitability metrics with ROE of 26.4% (75% above typical benchmarks), gross margin of 68.0% indicating strong pricing power, and operating margin of 27.4% showing operational excellence. Financial health is solid with debt-to-equity of 0.46 (63% lower than industry 1.27) and strong free cash flow of $12.5B supporting dividend sustainability. However, valuation concerns dominate with PEG ratio of 1.93 vs fair value of 1.0, and forward EPS growth of 9.8% significantly trailing industry 15.2%. P/E of 26.3x appears reasonable but growth justification is weak.
News Sentiment
Johnson & Johnson is making strategic moves to expand its market reach and accelerate drug development in early 2024. The healthcare giant recently announced it will launch four of its prescription drugs on the new TrumpRx government-backed platform, potentially opening new distribution channels and improving patient access. Meanwhile, the company is leveraging artificial intelligence to dramatically reduce drug development timelines, with executives claiming AI could cut the time to generate new drug leads in half. On the clinical front, JNJ's IMAAVY treatment for generalized myasthenia gravis continues to show promising results, with patients experiencing sustained disease control for over two years. The FDA has granted Priority Review status for IMAAVY, positioning it as potentially the first treatment of its kind. These developments come as JNJ's Innovative Medicine unit delivered strong Q1 performance, outpacing broader market expectations. The combination of expanded distribution access, AI-powered innovation, and promising clinical results suggests JNJ is positioning itself well for future growth, though investors remain focused on whether these initiatives can accelerate the company's currently modest growth trajectory.
Risk Assessment
Primary risk is valuation compression if growth disappoints - PEG of 1.93 leaves little margin for error. Healthcare regulatory changes and patent cliff risks for key drugs could impact future growth. Mitigation through position sizing at 2.5% and entry below current price to improve risk-reward.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is JNJ a halal stock?
Yes, Johnson & Johnson (JNJ) is halal-compliant per AAOIFI standards as of the latest quarterly review.
What is Plutrex's AI rating for JNJ?
Johnson & Johnson (JNJ) has a Plutrex AI rating of 72.5/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is JNJ a good investment?
According to Plutrex AI, JNJ has a Buy rating (72.5/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in JNJ?
US stocks like JNJ can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in JNJ?
Plutrex AI identifies the main risks for JNJ by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.